# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN
- Date: 2026-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Fairweather-Diaz, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week review on apalutamide and leuprolide. **S**

## History of present illness

Mr. Neruda returns four weeks after starting apalutamide and three weeks after his first leuprolide injection, with a professional Spanish interpreter. The right hip pain has eased to 2 of 10 and no longer wakes him; he takes acetaminophen once a day at most. He gets up to pass urine twice a night instead of three times. Mild hot flashes began last week. His energy is a little lower in the afternoons. He has had no rash, falls, dizziness, leg weakness or numbness. He saw his dentist a week ago; no dental work is needed. He takes vitamin D every day. The germline test result came back last week: no harmful variant was found. He had his radiotherapy planning visit, and treatment starts in two weeks. Before radiotherapy, his bowels are regular, once a day, with no bleeding. **S**

| Element | Detail |
|---|---|
| Treatment | Apalutamide four weeks; leuprolide three weeks ago |
| Symptoms | Pain 2 of 10; nocturia twice; mild hot flashes; no rash or falls |
| Results since last visit | Germline panel negative; dental examination clear |
| Next step | Radiotherapy to the prostate starts in two weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly lower afternoon energy; weight stable |
| Endocrine | Positive | Mild hot flashes for a week |
| Musculoskeletal | Positive | Right hip pain 2 of 10 |
| Integumentary | Negative | No rash or itch |
| Gastrointestinal | Negative | Bowels regular once a day; no bleeding |
| Neurological | Negative | No weakness, numbness or dizziness |

6 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet daily **S**
- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain **S**
- Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food **S**
- Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks **S**
- Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily **S**
- Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation **S**

## Allergies

- No known allergy **S**

## Objective

BP 152/90 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 92.8 kg; BMI 29.3 kg/m². All vital signs are synthetic.

PSA: 6.2 ng/mL (high); Total testosterone: 22 ng/dL (low); Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Glucose: 101 mg/dL (high); Creatinine: 0.98 mg/dL; eGFR (CKD-EPI 2021): 85 mL/min/1.73 m²; Calcium: 9.3 mg/dL; ALT: 25 U/L; AST: 23 U/L; Alkaline phosphatase: 141 U/L (high); Albumin: 4.1 g/dL; 25-hydroxyvitamin D: 28 ng/mL (low); TSH: 2.4 mIU/L; PHQ-2: 1; IPSS total (0 to 35): 14; Pain, 0 to 10: 2. All results are synthetic.

## Change since baseline

- PSA: 46.8 ng/mL (high) at baseline, 6.2 ng/mL (high) at this visit **S**
- Total testosterone: 468 ng/dL at baseline, 22 ng/dL (low) at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 101 mg/dL (high) at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 0.98 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 87 mL/min/1.73 m² at baseline, 85 mL/min/1.73 m² at this visit **S**
- Calcium: 9.6 mg/dL at baseline, 9.3 mg/dL at this visit **S**
- ALT: 22 U/L at baseline, 25 U/L at this visit **S**
- AST: 24 U/L at baseline, 23 U/L at this visit **S**
- Alkaline phosphatase: 168 U/L (high) at baseline, 141 U/L (high) at this visit **S**
- Albumin: 4.1 g/dL at baseline, 4.1 g/dL at this visit **S**
- 25-hydroxyvitamin D: 22 ng/mL (low) at baseline, 28 ng/mL (low) at this visit **S**
- IPSS total (0 to 35): 17 at baseline, 14 at this visit **S**
- Pain, 0 to 10: 6 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; walks without favoring the right hip |
| Cardiovascular | Regular rhythm; blood pressure 152/90 mm Hg on repeat; no ankle swelling |
| Skin | No rash |
| Neurological | Strength and sensation normal in both legs |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Metastatic hormone-sensitive prostate cancer on leuprolide and apalutamide** (C61). Early response: PSA 46.8 to 6.2 ng/mL, testosterone 22 ng/dL (castrate), alkaline phosphatase falling to 141 U/L, and less pain. The germline panel shows no pathogenic variant, so cascade testing of relatives is not needed; somatic testing of the biopsy is pending. **S**
   - Continue apalutamide 240 mg daily.
   - Radiotherapy to the prostate from two weeks' time.
   - Second leuprolide injection and three-month PSA at the next visit.
2. **Hypertension, higher on apalutamide** (I10). 152/90 mm Hg, up from 142/86, as expected when apalutamide speeds the breakdown of amlodipine. **S**
   - Amlodipine raised from 5 mg to 10 mg daily.
   - Home blood pressure readings sent through the portal in two weeks.
3. **Low bone mass with high fracture risk** (M85.89). Calcium 9.3 mg/dL; vitamin D 28 ng/mL and rising; dental examination clear. **S**
   - Denosumab 60 mg subcutaneously today, then every six months.
   - Continue cholecalciferol 2000 units daily; report numbness around the mouth or muscle cramps.
4. **Androgen deprivation with apalutamide** (Z79.899). Mild hot flashes and fatigue. TSH 2.4 mIU/L today; the baseline before apalutamide was not drawn. **S**
   - TSH every four months on apalutamide.
   - Report any rash early.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA on androgen deprivation | Every 3 to 6 months; an early value here for symptomatic disease | Completed today | 6.2 ng/mL, down from 46.8 |
| Laboratory | Testosterone | Every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Completed today | 22 ng/dL, castrate |
| Laboratory | Chemistry with calcium and alkaline phosphatase | Before denosumab; periodically in metastatic disease | Completed today | Calcium 9.3 mg/dL; creatinine 0.98 mg/dL; ALT 25 U/L; alkaline phosphatase 141 U/L, falling |
| Laboratory | 25-hydroxyvitamin D | Before a bone-protective drug and periodically | Completed today | 28 ng/mL, up from 22 |
| Laboratory | TSH on apalutamide | Periodically, about every four months | Completed today | 2.4 mIU/L, the first value, four weeks into treatment |
| Laboratory | Baseline TSH before apalutamide missed | Before starting apalutamide | Deferred | Ordered at the last visit but not drawn, a deviation from the protocol: the order was not on the laboratory requisition sent with the germline sample. Today's value is normal, so a pre-existing thyroid problem is unlikely and no harm has resulted, but a true baseline is lost. Corrective action: the apalutamide start checklist now includes TSH, drawn with the first prescription |
| Laboratory | Hemoglobin A1c and lipid panel | Baseline and yearly on androgen deprivation | Up to date | Baseline six weeks ago; A1c again at three months |
| Imaging | Bone density (DXA) | Every 1 to 2 years on androgen deprivation | Up to date | Baseline four weeks ago |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 152/90 mm Hg, above goal; amlodipine raised |
| Examination | Neurological check for spinal cord compression | Every visit with spinal metastases | Completed today | Normal |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Survey | Pain score | Every visit with symptomatic metastases | Completed today | 2 of 10, down from 6 |
| Survey | Urinary symptoms (IPSS) | Every follow-up visit | Completed today | IPSS 14, down from 17 |
| Survey | Bowel function before radiotherapy | Baseline before radiotherapy | Completed today | Regular once a day; no bleeding |
| Medication safety | Rash on apalutamide | Every visit on androgen deprivation | Completed today | None |
| Medication safety | Falls on apalutamide | Every visit on androgen deprivation | Completed today | No falls or dizziness |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Completed today | Mild; no treatment wanted |
| Medication safety | Denosumab: calcium, vitamin D and dental check before the first dose | Before each dose | Completed today | Calcium normal; vitamin D rising; dental examination clear a week ago; first dose given today |
| Referral | Germline testing result | Once | Completed today | No pathogenic variant on a multigene panel including BRCA1, BRCA2, ATM, CHEK2, PALB2, HOXB13 and the mismatch repair genes |
| Referral | Somatic tumor testing | Once, for metastatic disease | Ordered | Sent on the biopsy tissue; pending |
| Referral | Radiotherapy to the prostate | Once | Ordered | Planning done; 20 fractions start in two weeks |
| Survey | Cognition | Periodically on androgen deprivation | Due | Mini-Cog at the annual wellness visit |
| Self-management | Physical activity and calcium intake | Every visit | Completed today | Walking most afternoons; light resistance exercise started; calcium from food |

## Goal progress

- Diagnosis, staging and a shared treatment decision within three weeks of the first visit. Outcome by 2026-06-15: Biopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake. **S**
- Bone pain controlled, with a pain score of 2 or less and sleep restored. Outcome by 2026-07-13: Pain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivation. **S**
- PSA of 0.2 ng/mL or less within about seven months of starting treatment. In progress; target 2026-09-14. **S**
- Blood pressure below 130/80 mm Hg on androgen deprivation. In progress; target 2026-10-05. **S**
- Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk. In progress; target 2026-10-05. **S**
- Keep his morning writing and his official duties through treatment. In progress; target 2026-10-05. **S**

## Medication changes

- Stopped: Amlodipine 5 mg oral tablet, one tablet daily **S**
- Started: Amlodipine 10 mg oral tablet, one tablet daily **S**
- Started: Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026), American Urological Association and Society of Urologic Oncology
- ERLEADA (apalutamide) tablets: prescribing information (2026), Janssen Products, LP, via DailyMed (National Library of Medicine)
- CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026), Aether Forge

## Follow-up

- Radiotherapy from two weeks' time. Home blood pressure readings through the portal in two weeks. Review in nine weeks, at three months, with PSA, testosterone, blood count, chemistry, TSH and hemoglobin A1c, and the second leuprolide injection. **S**
- Next scheduled visit 2026-09-14: three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year. **S**
